Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats

Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats

Author Capitelli, Caroline Google Scholar
Sereniki, Adriana Google Scholar
Santos Lima, Marcelo Meira Autor UNIFESP Google Scholar
Reksidler, Angela Braga Google Scholar
Tufik, Sergio Autor UNIFESP Google Scholar
Barbato Frazao Vital, Maria Aparecida Google Scholar
Institution Univ Fed Parana
Universidade Federal de São Paulo (UNIFESP)
Abstract Parkinson's disease is a chronic neurological disease characterized by dopaminergic neuron degeneration in the substantia nigra pars compacta. Melatonin is a powerful antioxidant agent secreted by the pineal gland which has numerous physiological functions and seems to exert an important neuroprotective effect. the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model has been used to understand the pathophysiology of the disease because of its capacity to mimic biochemical and histological features observed in Parkinson's disease. This study investigated the effect of pretreatment with melatonin (50 mg/kg) on MPTP-lesioned animals 24 h and 7 days after neurotoxin infusion using the open-field test, two-way avoidance task and immunohistochemistry. Twenty-four hours after lesioning, the MPTP+vehicle group exhibited hypolocomotion and significant loss of tyrosine hydroxylase-immunoreactive cells, whereas no differences in these parameters were observed in lesioned animals receiving melatonin. Seven days after surgery, the MPTP-lesioned rats did not show hypolocomotion compared to control animals, while there was a significant dopaminergic neuronal loss. in the two-way avoidance task, MPTP-treated animals presented a cognitive deficit compared to the control groups and melatonin administration did not repair this defect. the present results suggest that melatonin reduces neuronal loss in the MPTP animal model of Parkinson's disease. (C) 2008 Published by Elsevier B.V.
Keywords active avoidance
cognitive impairment
Parkinson's disease
tyrosine hydroxylase
Language English
Sponsor Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Grant number FAPESP: 06/55968-6
Date 2008-10-10
Published in European Journal of Pharmacology. Amsterdam: Elsevier B.V., v. 594, n. 1-3, p. 101-108, 2008.
ISSN 0014-2999 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 101-108
Access rights Closed access
Type Article
Web of Science ID WOS:000259658300015

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account